(Q51717478)

English

Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis.

scientific article published in August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

phase III clinical trial

0 references

amyotrophic lateral sclerosis

0 references

Vincent Meininger

10

object named as

Vincent Meininger

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

Joseph L. Verheijde

6

object named as

Joseph Verheijde

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

author name string

Mohammed Sanjak

1

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Francois Salachas

2

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Elizabeth Frija-Orvoen

3

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Paul Theys

4

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Duncan Hutchinson

5

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Thomas Pianta

7

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Heather Stewart

8

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Benjamin Rix Brooks

9

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Patrice Douillet

11

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Xaliproden [SR57746A] ALS International Study Group

12

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

11

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

4

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

383-388

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Spirometry in the Lung Health Study. 1. Methods and quality control.

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Quality control of spirometry: a lesson from the BRONCUS trial

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.3109%2F17482960903486083

21 January 2018

Identifiers

10.3109/17482960903486083

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/20192884

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51717478&oldid=2165287489"